Skip to main content
PMC home page
Thorax logoLink to Thorax
. 1990 Jan;45(1):16–21. doi: 10.1136/thx.45.1.16

Almitrine bismesylate and oxygen therapy in hypoxic cor pulmonale.

T W Evans 1, J Tweney 1, J C Waterhouse 1, J Nichol 1, A J Suggett 1, P Howard 1
PMCID: PMC475633  PMID: 2108510

Abstract

The effect of oral treatment with the thiazine derivative almitrine bismesylate was studied in 28 patients with chronic obstructive pulmonary disease and arterial hypoxaemia receiving long term domiciliary oxygen therapy in a placebo controlled, double blind crossover trial. The initial treatment was given for three months and the second for two months. Because almitrine had an unexpectedly prolonged washout effect crossover analysis could not be performed; data from the placebo treatment administered in the second arm of the trial were used to calculate the half life of almitrine. Nine patients were withdrawn from the study (5 almitrine, 4 placebo). Patients' tolerance of the drug was good. The estimated plasma half life of almitrine was 20.5 days, considerably longer than previously reported. Almitrine caused a significant improvement in arterial oxygen tension (PaO2) with a mean maximum increase of 0.7 kPa at a plasma concentration of 500 ng/ml. Higher plasma concentrations were not associated with any further increase in PaO2. There was no significant effect on arterial carbon dioxide tension (PaCO2). In a second, acute study at the end of each arm of the chronic trial nine patients were subjected to increasing oxygen delivery rates (2, 4, and 6 l/min) for 90 minutes or until blood gas concentrations plateaued. Almitrine increased PaO2 in a dose dependent fashion at all delivery rates, but the effect diminished as PaO2 approached normoxic levels. There was no significant effect on PaCO2. Almitrine treatment results in a significant improvement in PaO2 over that achieved by oxygen alone, an effect that diminishes at high flow rates. Whether this is of clinical benefit is not known. In view of the prolonged half life revised dosage schedules are required.

Full text

PDF
16

Images in this article

19Image
on p.19
19Image
on p.19

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baune A., Bromet N., Courte S., Voisin C. Trace determination of almitrine in plasma by gas-liquid chromatography using a nitrogen-phosphorus detector. J Chromatogr. 1981 Apr 10;223(1):219–224. [PubMed] [Google Scholar]
  2. Bell R. C., Mullins R. C., 3rd, West L. G., Bachand R. T., Johanson W. G., Jr The effect of almitrine bismesylate on hypoxemia in chronic obstructive pulmonary disease. Ann Intern Med. 1986 Sep;105(3):342–346. doi: 10.7326/0003-4819-105-3-342. [DOI] [PubMed] [Google Scholar]
  3. Bickerman H. A., Chusid E. L. The case against the use of respiratory stimulants. Chest. 1970 Jul;58(1):53–56. doi: 10.1378/chest.58.1.53. [DOI] [PubMed] [Google Scholar]
  4. Bone R. C., Pierce A. K., Johnson R. L., Jr Controlled oxygen administration in acute respiratory failure in chronic obstructive pulmonary disease: a reappraisal. Am J Med. 1978 Dec;65(6):896–902. doi: 10.1016/0002-9343(78)90740-4. [DOI] [PubMed] [Google Scholar]
  5. Evans T. W., Waterhouse J., Howard P. Clinical experience with the oxygen concentrator. Br Med J (Clin Res Ed) 1983 Aug 13;287(6390):459–461. doi: 10.1136/bmj.287.6390.459. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Fishman A. P. State of the art: chronic cor pulmonale. Am Rev Respir Dis. 1976 Oct;114(4):775–794. doi: 10.1164/arrd.1976.114.4.775. [DOI] [PubMed] [Google Scholar]
  7. Gelb A. F., Klein E., Schiffman P., Lugliani R., Aronstam P. Ventilatory response and drive in acute and chronic obstructive pulmonary disease. Am Rev Respir Dis. 1977 Jul;116(1):9–16. doi: 10.1164/arrd.1977.116.1.9. [DOI] [PubMed] [Google Scholar]
  8. Hlastala M. P., McKenna H. P., Middaugh M., Robertson H. T. Role of diffusion-dependent gas inhomogeneity in gas exchange in the dog. Bull Eur Physiopathol Respir. 1982 Mar-Apr;18(2):373–380. [PubMed] [Google Scholar]
  9. Howard P. Almitrine bismesylate (Vectarion). Bull Eur Physiopathol Respir. 1984 Mar-Apr;20(2):99–103. [PubMed] [Google Scholar]
  10. MacLeod C. N., Thomas R. W., Bartley E. A., Parkhurst G. W., Bachand R. T. Effects and handling of almitrine bismesylate in healthy subjects. Eur J Respir Dis Suppl. 1983;126:275–289. [PubMed] [Google Scholar]
  11. Middleton H. C., Peake M. D., Howard P. Hypoxaemia in chronic obstructive bronchitis. Thorax. 1979 Apr;34(2):213–216. doi: 10.1136/thx.34.2.213. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Mélot C., Naeije R., Rothschild T., Mertens P., Mols P., Hallemans R. Improvement in ventilation-perfusion matching by almitrine in COPD. Chest. 1983 Mar;83(3):528–533. doi: 10.1378/chest.83.3.528. [DOI] [PubMed] [Google Scholar]
  13. Naeije R., Mélot C., Mols P., Hallemans R., Naeije N., Cornil A., Sergysels R. Effects of almitrine in decompensated chronic respiratory insufficiency. Bull Eur Physiopathol Respir. 1981;17(2):153–161. [PubMed] [Google Scholar]
  14. Powles A. C., Tuxen D. V., Mahood C. B., Pugsley S. O., Campbell E. J. The effect of intravenously administered almitrine, a peripheral chemoreceptor agonist, on patients with chronic air-flow obstruction. Am Rev Respir Dis. 1983 Mar;127(3):284–289. doi: 10.1164/arrd.1983.127.3.284. [DOI] [PubMed] [Google Scholar]
  15. Proceedings of the British Thoracic Society. 1985 winter meeting. 11-12 December, London. Abstracts. Thorax. 1986 Mar;41(3):224–256. doi: 10.1136/thx.41.3.224. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Rudolf M., Banks R. A., Semple S. J. Hypercapnia during oxygen therapy in acute exacerbations of chronic respiratory failure. Hypothesis revisited. Lancet. 1977 Sep 3;2(8036):483–486. doi: 10.1016/s0140-6736(77)91606-3. [DOI] [PubMed] [Google Scholar]
  17. Simonneau G., Meignan M., Denjean A., Raffestin B., Harf A., Prost J. F. Cardiopulmonary effects of a single oral dose of almitrine at rest and on exercise in patients with hypoxic chronic airflow obstruction. Chest. 1986 Feb;89(2):174–179. doi: 10.1378/chest.89.2.174. [DOI] [PubMed] [Google Scholar]
  18. Stanley N. N., Galloway J. M., Gordon B., Pauly N. Increased respiratory chemosensitivity induced by infusing almitrine intravenously in healthy man. Thorax. 1983 Mar;38(3):200–204. doi: 10.1136/thx.38.3.200. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Stradling J. R., Barnes P., Pride N. B. The effects of almitrine on the ventilatory response to hypoxia and hypercapnia in normal subjects. Clin Sci (Lond) 1982 Oct;63(4):401–404. doi: 10.1042/cs0630401. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES